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Introduction
The Janus-associated kinase 2 (JAK2) V617F mutation is 
detected in over 95% of patients with polycythemia vera (PV) 
and in about 50% of cases of essential thrombocythemia 
( E T )  a n d  p r i m a r y  m y e l o f i b r o s i s  ( P M F )  ( 1 - 3 ) . 
Transformation of myeloproliferative neoplasms (MPN) 
into acute myelogenous leukemia (AML) is a well-studied 
and reported phenomenon (2,4,5). Both transformation 
of ET to AML (6,7), as well as a JAK2 V617F mutation in 
de novo AML are very rare (8). Amongst all subtypes of 
AML originating from MPN, acute promyelocytic leukemia 
(APL) is extremely rare. In the English literature there have 
been only 9 such cases reported to date (1,7,9-14). In the 
same literature search we have not found any case of APL 
with concurrent diagnosis of MPN. Herein, we present 
the case of a young male with new onset APL and JAK2 
positive MPN.
Case presentation
A young male (<40 years old) was referred to our hospital 
for gingival bleeding, pancytopenia and fever. The patient 
had previously presented with fever, sore throat, and 
tonsillar enlargement and had been treated empirically 
for pharyngitis with antibiotics. He also reported gingival 
bleeding and several episodes of epistaxis as well as dark 
stools in the few weeks preceding admission. Physical 
examination was significant for gingival bleeding and 
enlarged tonsils. Abdominal ultrasonography revealed 
splenomegaly with longest diameter of 14.3 cm. A complete 
blood count on admission was remarkable for a white blood 
count (WBC) of 2.1×109/L, hemoglobin (Hgb) of 9.8 g/dL, 
and platelet count of 11×109/L. The peripheral blood smear 
revealed 10% blasts and 42% promyelocytes. Bone marrow 
biopsy done on admission showed sheets of immature 
atypical myeloid cells, comprising more than 90% of 
the marrow cellularity. Those cells showed moderate to 
abundant cytoplasm, irregular nuclei (some of which were 
indented or bilobed), smudged chromatin and prominent 
nucleoli. Maturing myeloid elements including segmented 
neutrophils were not seen; megakaryocytes and erythroid 
precursors were markedly decreased. No reticulin fibrosis 
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was seen. Karyotyping revealed t(15;17)(q24;q21) in all 
20 metaphases analyzed. Molecular studies were positive 
for PML/RARa, FLT3 TKD and JAK2 V617F mutations 
(Table 1). Additional molecular studies for genes associated 
with MPN, MDS, and AML were negative (Table 2) (15). 
The patient was immediately started on all-trans retinoic 
acid (ATRA). Arsenic trioxide (ATO) was added on day 
10 according to the reported regimen for clinically low-risk 
APL (16). The hospital course was complicated by 
differentiation syndrome with a high WBC (Figure 1A) and 
pleural and pericardial effusions for which a short course 
of dexamethasone was given. Surprisingly, a rapid increase 
in platelet count was observed during count recovery, 
with values reaching as high as 1,700×109/L (Figure 1B). 
Bone marrow biopsy at this point showed increased reticulin 
fibrosis, a left shift in myeloid lineage cells with dysplastic and 
an increased number of megakaryocytes. The morphology 
overall was reported to be consistent with MPN (PMF/ET). 
A FISH panel for myelodysplasia was negative and a 
chromosome study revealed a normal karyotype: 46 XY. 
Molecular studies were negative for the FLT3 TKD, but remained 
positive for the JAK2 V617F mutation. The PML/RARa 
was still detectable by PCR post-induction therapy with 
ATRA and ATO. The patient was started on consolidation 
chemotherapy with cytarabine and idarubicin for a total of 
two cycles. He continued ATRA throughout consolidation. 
The patient became PCR negative for PML/RARa 
a f ter  complet ion of  two cyc les  of  consol idat ion 
chemotherapy, however the JAK2 mutation remained 
positive (Table 1). At that point the patient had a normal 
WBC but a high platelet count, with platelets as high as 
949×109/L. Since the patient presented with leukemia 
transformation, peak counts of platelets were higher than 
1,500×109/L, and bone marrow biopsy revealed dysplastic 
megakaryocytes as well as reticulin fibrosis, we believe that 
this patient might more likely have PMF than ET, and had 
high risk PMF/ET, even though he was younger than 40 (17). 
Therefore, low dose aspirin (81 mg) and hydroxyurea 
1,000 mg daily were given for the PMF/ET. Interferon and 
ruxolitinib were discussed but clinically impractical at the 
time. The patient was also placed on maintenance treatment 
for APL with ATRA every 3 months. 
Discussion
Both ET and PV may progress to myelofibrosis, and 
all MPNs may evolve into AML. The most common to 
transform in this way is PMF, occurring in about 15% 
Table 1 Cytogenetic and molecular profiles in the course of leukemia treatment
Date t(15;17) PML/RARa JAK2 V617F (%) FLT3 ITD FLT3 TKD
7/19/2015 Positive [20/20] Positive 34.00 Negative Positive
8/17/2015 Negative Weak positive 25.60 Negative Negative
11/17/2015 ND Negative 24.11 ND ND
ITD, internal tandem duplication; TKD, tyrosine kinase domain mutation at D835; ND, not done.
Table 2 Molecular profiling by next generation sequencing of the bone marrow specimen
Profile Genes Result
MPN BCR/ABL, MPL, CALR, CSF3R, SETBP1 –
MDS ASXL1, ETV6, EZH2, RUNX1, TP53 –
AML
RNA splicing SF3B1, SRSF2, U2AF1, ZRSR2 –
Epigenetic ASXL1, DNMT3A, EZH2, IDH1/2, SETBP1, TET2 –
Transcription factors CEBPa, ETV6, GATA2, PHF6, RUNX1, WT1 –
Cohesion complex RAD1, SMC1A, SMC3, STAG2 –
Activated signaling BRAF, CBL, KIT, KRAS, MPL, NF1, NRAS, PDGFa/b, PTPN11, STAT3, STAT5B –
Other BCOR, CALR, CSF3R, NPM1,TP53 –
–, negative. MPN, myeloproliferative neoplasm; MDS, myelodysplastic syndrome; AML, acute myeloid leukemia. 
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of cases (1,18). Such transformation happens even less 
frequently in patients with ET (6,7). In the majority of 
PV cases there are clones homozygous for JAK2 V617F 
mutations, which are rarely found in ET (19,20). JAK2 
V617F mutations are very rare in de novo AML (8). 
Amongst all subtypes of AML originating from MPNs, 
APL has been reported the least frequently. Only 2 of the 
early case reports had molecularly documented PML/RARa 
mutation (7,12) (Table 3). The JAK2 V617F mutation status 
was unknown in 8 of the cases (1), as they were reported 
prior to the 2005 discovery of the JAK2 mutation (21,22). 
The association between APL and MPNs was thought to be 
due to promyelocytic blastic crisis of MPN, APL secondary 
to cytoreductive therapy, and de novo APL (7). Braun at al. 
recently reported a case of APL with PML/RARα and 
JAK2 V617F mutation (1). The authors postulated that 
the inflammatory response resulting from the chemokine 
release (CLL-2 and IL-8) from ATRA-treated APL cells 
was accentuated by inflammatory downstream signalling 
from the JAK-2 mutation and that this led to severe 
differentiation syndrome. JAK-2 inhibition by ruxolitinib 
in the in vitro studies on NB-4 APL cells treated with 
ATRA did not affect CLL-2 and IL-8 levels, supporting the 
importance of JAK2 in downstream activation as previously 
described (1,2). However, the role of JAK-2 inhibition in 
the management of differentiation syndrome has not been 
Figure 1 White blood counts and platelet counts during induction and consolidation chemotherapy. (A) The high WBC was observed 
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Table 3 Case reports on transformation of myeloproliferative neoplasms to acute promyelocytic leukemia
Underlying MPN Prior treatment Years since diagnosis References
ET→PMF Hydroxyurea, aspirin, ruxolitinib 16.0→2.0 (1)
ET None 9.3 (7)
ET Uracil, mustard 3.9 (13)
ET Busulfan 5.2 (14)
ET Hydroxyurea 1.7 (11)
ET Hydroxyurea, warfarin 4.0 (12)
PV Phlebotomy 2.0 (12)
PV Phlebotomy 9.3 (10)
PMF Hydroxyurea 6.8 (9)
MPN, myeloproliferative neoplasm; ET, essential thrombocythemia; PMF, primary myelofibrosis; PV, polycythemia vera.
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clinically proven. In the patient presented by Braun et al. 
the diagnosis of MPN predated the diagnosis of APL. Our 
report presents for the first time a case of APL diagnosed 
concurrently with a MPN. It is highly possible that the 
APL clone remained dominant and masked the phenotype 
of MPN at the time of diagnosis. The MPN clone became 
dominant after the APL clone was suppressed. It remains 
unknown whether the APL clone arose from the MPN 
clone since we were not able to perform single cell genome 
analysis prior to the initiation of the APL therapy like 
in those cases reported in the literature (23-25). Since 
splenomegaly and FLT3-TKD were also present at the 
time of diagnosis, we hypothesize that the JAK2 V617F 
mutated MPN clone (likely PMF) was present first and 
that additional mutations like FLT3 and PML/RARa took 
place later and then led to the development of APL (26-32). 
It is of interest to point out that the case of APL 
transformed from a known diagnosis of ET with fibrosis 
also was found to have FLT3-TKD (D835 mutation) 
in addition to JAK2 V617F mutation (1). These two 
cases of APL transformation from ET /PMF containing 
FLT3-TKD mutation make it likely that FLT3-TKD 
mutation plays a driver role for this transformation process 
involving PML/RARa.
Conclusions
This is the first case with molecular data showing co-
existence of PML/RARa, FLT3-TKD, and a JAK2 V617F 
mutation at the time of APL diagnosis. We hypothesize that 
the JAK2 V617F mutated MPN clone was present first, and 
that additional mutations like FLT3 and PML/RARa took 
place later and then led to the development of APL.
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